Inclusion Criteria:

1. Patients with histologically or cytologically confirmed diagnosis of locally advanced
squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx stage
III, IVa or IVb

2. Measurable disease defined as one or more target lesions according to RECIST based
onCT scan or MRI and clinical evaluation

3. Eligible for intended curative radiotherapy

4. Patients considered ineligible for platinum based chemotherapy based on
investigator's judgment

5. Age > 18 years

6. Following receipt of verbal and written information about the study, the patient must
provide signed informed consent before any study related activity is carried out

Exclusion Criteria:

1. Prior radiotherapy to the head and neck area

2. Prior chemotherapy administered for cancer in the head and neck area

3. Prior targeted therapy (e.g. EGFR antibodies or EGFR inhibitors)

4. Received the following treatments within 4 weeks prior to Visit 2:

1. Retinoic acid

2. Other immunosuppressive drugs (e.g. drugs interfering with the functions of T
cells, IL-2 or equivalent)

3. Any non-marketed drug substance

5. Past or current malignancy other than SCCHN, except for:

- Cervical carcinoma Stage 1B or less

- Non-invasive basal cell skin carcinoma

- Squamous cell skin carcinoma

- Stage 1 or 2 treated prostate cancer with PSA in the normal range for >2 years
post treatment

- Malignant melanoma with a complete response duration of > 10 years

- Other cancer diagnoses with a complete response duration of > 5 years

6. Metastatic SCCHN disease

7. Chronic or current infectious disease such as, but not limited to, chronic renal
infection and tuberculosis

8. Clinically significant cardiac disease including unstable angina, acute myocardial
infarction within six months before Visit 1, congestive heart failure, and arrhythmia
requiring anti-arrhythmic therapy, with the exception of extra systoles or minor
conduction abnormalities

9. Significant concurrent, uncontrolled medical condition including, but not limited
to,hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological,
cerebral or psychiatric disease considered to preclude trial treatment and/or
compliance according to the Investigator's opinion, or any other condition preventing
therapy according to the Investigator's opinion

10. Known HIV positive

11. Known active hepatitis B and/or hepatitis C

12. Screening laboratory values:

- Neutrophils < 1.5 x 109/L

- Platelets < 100 x109/L

- Hemoglobin < 6 mmol/L

13. Current participation in any other interventional clinical study

14. Patients known or suspected of not being able to comply with a study protocol (e.g.
due to alcoholism, drug dependency, or psychological disorder)

15. Known or suspected hypersensitivity to components of the investigational medicinal
Product

16. Breast feeding women or women with a positive pregnancy test at screening blood
Sample

17. Males not willing to use adequate contraception during study and for 12 months after
last dose of zalutumumab or women of childbearing potential not willing to use
adequate contraception as hormonal birth control or intrauterine device during study
and for 12 months after last dose of zalutumumab